Plant Comparison

Perforate St John’s-wort vs Field scabious

A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant APerforate St John’s-wortHypericum perforatumHypericaceaeFull monograph →
Plant BField scabiousKnautia arvensisCaprifoliaceaeFull monograph →

At a glance

Perforate St John’s-wort and Field scabious: they share 5 indicated uses (eczema, infection (general), inflammation (general), …); 2 pharmacological actions in common.

Perforate St John’s-wortField scabious
Constituents34
Pharmacological actions64
Indicated uses96
Safety notes22
Cited sources318
Indicated uses
Only Perforate St John’s-wort
Arthritis / joint painBruisingCold & fluInsomnia / sleeplessness
Shared (5)
EczemaInfection (general)Inflammation (general)Skin irritationWounds
Only Field scabious
Acne
Pharmacological actions
Only Perforate St John’s-wort
AntiviralEmollient / skin-soothingSedative / sleep supportVulnerary (wound healing)
Shared (2)
Anti-inflammatoryAntioxidant
Only Field scabious
Alterative / depurative ('detox')Antimicrobial

Evidence face-off — shared uses

ConditionPerforate St John’s-wortField scabiousVerdict
Eczema1/102/10Comparable evidence
Infection (general)1/102/10Comparable evidence
Inflammation (general)1/107/10Stronger for Field scabious
Skin irritation1/102/10Comparable evidence
Wounds1/102/10Comparable evidence

Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Naphthodianthrones (hypericin, pseudohypericin)[4]

Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.

Phloroglucinols (hyperforin)[4]

Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.

Hyperforin
Flavonoids (hyperoside, quercetin, rutin)[4]

Antioxidant flavonoids contributing to overall activity.

FlavonoidsQuercetinRutin
Phenolic acids (chlorogenic and dicaffeoylquinic acids)[1, 2]

Chlorogenic, cryptochlorogenic and dicaffeoylquinic acids and caffeoylhydrocitric acid (antioxidant).

Phenolic acidsChlorogenic acidCaffeic acid
Flavonoids (C-flavone glycosides, isovitexin)[1, 2]

C-glycosidic flavones such as isovitexin and related flavonoids.

FlavonoidsApigenin
Triterpenoid saponins (knautiosides)[3, 5]

Saponin glycosides (knautiosides) characteristic of the plant and the Caprifoliaceae family.

Triterpene saponinsSaponins
Iridoid glycosides[3, 8]

Iridoid glycosides typical of the honeysuckle family (Caprifoliaceae/Dipsacaceae).

Iridoid glycosides

Pharmacological Actions

Anti-inflammatory[5, 15, 16]
Antioxidant[6, 15, 16]
Antiviral[15, 16]
Emollient / skin-soothing[15, 16]
Sedative / sleep support[1, 2, 4, 5, 9, 11, 12, 13, 14, 15, 16]
Vulnerary (wound healing)[4, 15, 16]
Alterative / depurative ('detox')[3, 4]

Traditional 'blood purifier' (depurative) for skin complaints; the classic use of field scabious.

Anti-inflammatory[4, 6]

Knautia and related Caprifoliaceae extracts inhibit inflammatory mediators (COX/LOX).

Antioxidant[4, 6, 7]
Antimicrobial[4, 8]

Antibacterial (anti-acne) activity of Knautia extracts; antimicrobial activity across the family.

Traditional & Indicated Uses

Arthritis / joint pain[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Bruising[15, 16]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Bruising
Cold & flu[15, 16]Traditional · 1/10

inferred from antiviral action

Evidence: 1
Label: Cold & flu
Eczema[15, 16]Traditional · 1/10

inferred from emollient action

Evidence: 1
Label: Eczema
Infection (general)[15, 16]Traditional · 1/10

inferred from antiviral action

Evidence: 1
Label: Infection (general)
Inflammation (general)[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Insomnia / sleeplessness[15, 16]Traditional · 1/10

inferred from sedative action

Evidence: 1
Label: Insomnia / sleeplessness
Skin irritation[15, 16]Traditional · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Wounds[15, 16]Traditional · 1/10

inferred from vulnerary action

Evidence: 1
Label: Wounds
Skin irritation[3, 4]Traditional · 2/10

Traditional remedy for eczema, itching and skin complaints; anti-acne activity of Knautia extracts.

Evidence: 2
Label: Skin irritation
Eczema[4]Traditional · 2/10

inferred from traditional skin/depurative use

Evidence: 2
Label: Eczema
Acne[4]Traditional · 2/10

Anti-acne activity of Knautia species extracts (antibacterial, anti-inflammatory).

Evidence: 2
Label: Acne
Inflammation (general)[4, 6]Good · 7/10
Evidence: 7
Label: Inflammation (general)
Wounds[4]Traditional · 2/10

inferred from traditional external use on cuts and sores

Evidence: 2
Label: Wounds
Infection (general)[4, 8]Traditional · 2/10

inferred from antimicrobial action

Evidence: 2
Label: Infection (general)

Safety, Cautions & Contraindications

Safety note[15, 16]Caution

Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.

Safety note[15, 16, 17]Caution

Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).

Safety noteCaution

Very little is known about the safety of field scabious and there are no clinical data; avoid medicinal doses in pregnancy and breastfeeding and use only modest amounts.

Safety note[5]Info

Most pharmacological data come from closely related Caprifoliaceae (genus Knautia, Scabiosa, Dipsacus) rather than Knautia arvensis itself; apply to field scabious with caution.

External Ids

Gbif: 3189486
Powo: urn:lsid:ipni.org:names:433719-1
Wikidata: Q158289
Gbif: 2888808
Wikidata: Q27648

Botanical Description

Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]

Height: 30-90 cm
Habit: Erect, branching perennial herb
Leaves: Paired, oval, dotted with tiny translucent oil glands
Flowers: Bright yellow, five-petalled, with numerous stamens and black-dotted petal edges, in flat-topped clusters
Stem: Erect, branching, with two raised longitudinal ridges
Root: Woody rootstock with spreading rhizomes
Fruit: Small, three-valved capsule
Flowering Period: June-September (traditionally around St John's Day, 24 June)

A hairy perennial herb of the honeysuckle family (formerly Dipsacaceae), 25-100 cm tall, growing from a stout rootstock. The stems are roughly hairy and bear opposite leaves that are variable - the lower ones often lyre-shaped or pinnately lobed, the upper deeply cut. The flowers are massed into flat, domed pincushion heads about 3-4 cm across, lilac to bluish-violet, with the outer florets enlarged; the heads are carried on long stalks and, unlike true scabious (Scabiosa), the receptacle is hairy rather than scaly. It flowers through summer and is a favourite of bees and butterflies.[1]

Height: 25-100 cm
Habit: Hairy perennial herb from a stout rootstock
Leaves: Opposite, hairy; lower leaves lyre-shaped/pinnately lobed, upper deeply cut
Flowers: Lilac to bluish-violet florets in flat, domed pincushion heads 3-4 cm across, outer florets enlarged
Stem: Erect, roughly hairy, branched above
Root: Stout rootstock with fibrous roots
Fruit: A small hairy achene enclosed in an epicalyx
Flowering Period: July-September

Habitat

Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]

Dry grassland, meadows, pastures, dry hills, roadside banks, field margins and open woods, on well-drained and often calcareous soils across Europe and into western Asia and parts of Africa. A characteristic plant of unimproved dry meadows.[1]

Harvesting

The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]

Parts: Flower, Leaf
Season: Summer, at flowering

The flowering aerial parts (leaves, stems, flower heads) are gathered in summer while in flower and dried; the root is also used. Best cut from established plants in dry grassland.[1]

Parts: Aerial parts, Flower, Root
Season: Aerial parts in flower (July-September); root in autumn

Traditional Uses

St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]

Field scabious has a European folk-medicine reputation chiefly as a remedy for skin complaints - eczema, itching, scabies (the name 'scabious' comes from its use against 'the scab'), cuts and sores - taken internally as a 'blood purifier' (alterative/depurative) and applied externally as a wash or poultice. It has also been used for coughs and sore throats. The plant is rich in phenolic acids, flavonoids and saponins; the closely related genera Knautia, Scabiosa and Dipsacus in the honeysuckle family share this chemistry and a tradition of use in skin disease and inflammation.[3, 4]

Preparations

Standardised extract[1]

Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.

Infusion[3]

The dried flowering herb infused as a tea traditionally taken as an alterative ('blood purifier') for skin complaints and for coughs.

Wash / poultice[4]

A strong infusion or the crushed herb applied externally to eczema, itching, cuts and sores (traditional).

Dosage

Standardised extract[1]

Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.

Not documented

Drug Class Interactions

Safety note[18, 19, 20, 21]Avoid
Drug Class: antidepressants-serotonergic
Mechanism: St John's wort raises serotonin activity; combined with SSRIs, SNRIs or MAOIs it can trigger serotonin syndrome (agitation, tremor, sweating, rapid heartbeat). Reviews of clinical reports document serotonin syndrome and lethargy when it is combined with serotonin-reuptake inhibitors.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 22]Avoid
Drug Class: antiretrovirals
Mechanism: Potent CYP3A4 and P-glycoprotein induction lowers antiretroviral levels (indinavir exposure fell ~57%), risking loss of viral control and drug resistance.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 23]Avoid
Drug Class: immunosuppressants
Mechanism: Enzyme and transporter induction reduces ciclosporin and tacrolimus levels; reported to cause subtherapeutic concentrations and transplant rejection.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 24, 25, 26]Avoid
Drug Class: hormonal-therapies
Mechanism: Increased metabolism of ethinylestradiol and progestins reduces contraceptive exposure, causing breakthrough bleeding, ovulation and unplanned pregnancy. Randomised and controlled trials in women confirmed more breakthrough bleeding, reduced progestin levels and evidence of ovulation when St John's wort was added to the pill.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: anticoagulants-antiplatelets
Mechanism: CYP induction increases warfarin clearance and can lower INR, reducing the anticoagulant effect; close monitoring is needed.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 27]Caution
Drug Class: cardiac-glycosides
Mechanism: P-glycoprotein induction lowers digoxin levels (AUC fell ~25% over ten days), which may reduce its effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: statins
Mechanism: CYP3A4 induction lowers levels of simvastatin and atorvastatin, potentially weakening their cholesterol-lowering effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[18, 19, 21]Caution
Drug Class: cyp3a4-substrates
Mechanism: As a broad CYP3A4 and P-glycoprotein inducer, St John's wort can lower levels of many medicines cleared by this pathway; check each medication individually.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Safety note[20, 28, 29]Avoid
Drug Class: chemotherapy-agents
Mechanism: St John's wort strongly induces CYP3A4 and P-glycoprotein, speeding the breakdown and removal of several cancer medicines. In patients it cut the active form of irinotecan (SN-38) by about 42% and reduced imatinib exposure by roughly a third - enough to weaken treatment and risk drug resistance. Do not take St John's wort during chemotherapy.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Not documented

References

REF-0842, REF-0843, REF-0844, REF-1789, REF-1790, REF-1791, REF-1792, REF-1793, REF-1794, REF-1795, REF-1796, REF-1797, REF-1798, REF-1799
REF-2808, REF-2809, REF-2810, REF-2811, REF-2812, REF-2813, REF-2814, REF-2815

Pairings

St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]

Partner Id: crocus-sativus
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]

Partner Id: rhodiola-rosea
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]

Partner Id: valeriana-officinalis
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]

Partner Id: piper-methysticum
Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Not documented

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

[1]

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-10

Synonyms

Not documented

Scabiosa arvensis, Knautia arvensis subsp. arvensis

References & Sources

  1. Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
    https://doi.org/10.1016/j.jad.2016.12.048
  2. Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
    https://doi.org/10.1007/s00210-022-02229-z
  3. Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
    https://doi.org/10.1016/S0140-6736(99)06457-0
  4. Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
    https://doi.org/10.22038/IJBMS.2022.65112.14338
  5. Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
    https://doi.org/10.1016/j.phymed.2024.155847
  6. Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
    https://doi.org/10.3389/fpls.2016.01004
  7. Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
    https://doi.org/10.1002/ptr.5050
  8. Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
    https://doi.org/10.1016/j.jep.2010.07.034
  9. Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
    https://doi.org/10.1016/j.lfs.2004.04.005
  10. Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
    https://doi.org/10.3109/13697137.2013.861814
  11. Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
    https://doi.org/10.2165/00003088-200645050-00002
  12. Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
    https://doi.org/10.1055/s-2001-15467
  13. Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
    https://doi.org/10.1038/sj.mp.4000557
  14. Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
    https://doi.org/10.2174/1568026033392589
  15. Linde, K. et al (2008) 'St John'. Traditional / reference
    https://scholar.google.com/scholar?q=St%20John
  16. Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
    https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St
  17. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  18. Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
    https://doi.org/10.1177/0269881104042632
  19. Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
    https://doi.org/10.2165/11317010-000000000-00000
  20. Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
    https://doi.org/10.1208/s12248-009-9146-8
  21. Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
    https://doi.org/10.1111/bph.14936
  22. Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
    https://doi.org/10.1016/S0140-6736(99)05712-8
  23. Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
    https://doi.org/10.1345/aph.10088
  24. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  25. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  26. Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
    https://doi.org/10.1046/j.1365-2125.2003.02005.x
  27. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
    https://doi.org/10.1053/cp.1999.v66.a101944
  28. Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
    https://doi.org/10.1093/jnci/94.16.1247
  29. Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
    https://doi.org/10.1592/phco.24.16.1508.50958
  30. Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
    https://doi.org/10.5414/cpp42139
  31. Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
    https://doi.org/10.3390/ph19030399
  1. Karalija, E. and Muratovic, E. and Tarkowski, P. and Zeljkovic, S.C (2017) 'Variation in Phenolic Composition of Knautia arvensis in Correlation with Geographic Area and Plant Organ', Natural Product Communications, 12(4), pp. 545-548. doi:10.1177/1934578x1701200421 Preclinical
    https://doi.org/10.1177/1934578x1701200421
  2. Moldoch, J. and Szajwaj, B. and Masullo, M. and Pecio, L. and Oleszek, W. and Piacente, S. and Stochmal, A (2011) 'Phenolic constituents of Knautia arvensis aerial parts', Natural Product Communications, 6(11), pp. 1627-1630. doi:10.1177/1934578x1100601117 Preclinical
    https://doi.org/10.1177/1934578x1100601117
  3. Plouvier, V (1971) 'Research on heterosides: knautioside and saponosides from Knautia arvensis and related glycosides', Comptes Rendus de l'Academie des Sciences, Serie D, 272(10), pp. 1443-1446. Preclinical
    https://scholar.google.com/scholar?q=Research%20on%20heterosides%3A%20knautioside%20and%20saponosides%20from%20Knautia%20arvensis%20and%20related%20glycosides
  4. Chrzaszcz, M. and Miazga-Karska, M. and Klimek, K. and Dybowski, M.P. and Typek, R. and Tchorzewska, D. and Dos Santos Szewczyk, K (2023) 'The Anti-Acne Potential and Chemical Composition of Knautia Species (Caprifoliaceae) Extracts', International Journal of Molecular Sciences, 24(11), pp. 9188. doi:10.3390/ijms24119188 Preclinical
    https://doi.org/10.3390/ijms24119188
  5. Skala, E. and Szopa, A (2023) 'Dipsacus and Scabiosa Species - The Source of Specialized Metabolites with High Biological Relevance: A Review', Molecules, 28(9), pp. 3754. doi:10.3390/molecules28093754 Meta-analysis / review
    https://doi.org/10.3390/molecules28093754
  6. Pinto, D.C.G.A. and Rahmouni, N. and Beghidja, N. and Silva, A.M.S (2018) 'Scabiosa Genus: A Rich Source of Bioactive Metabolites', Medicines (Basel), 5(4), pp. 110. doi:10.3390/medicines5040110 Meta-analysis / review
    https://doi.org/10.3390/medicines5040110
  7. Albayrak, S. and Aksoy, A. and Yilmaz, M.A. and Beyzi, E (2024) 'Investigation of Phytochemical, Antioxidant and Antidiabetic Potentials of Scabiosa L. (Caprifoliaceae) Species with Chemometric Methods', Chemistry and Biodiversity, 21(2), pp. e202301652. doi:10.1002/cbdv.202301652 Preclinical
    https://doi.org/10.1002/cbdv.202301652
  8. Saar-Reismaa, P. and Koel, M. and Tarto, R. and Vaher, M (2022) 'Extraction of bioactive compounds from Dipsacus fullonum leaves using deep eutectic solvents', Journal of Chromatography A, 1677, pp. 463330. doi:10.1016/j.chroma.2022.463330 Preclinical
    https://doi.org/10.1016/j.chroma.2022.463330

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.